Clinical trials: Endstage Kidney Disease
Endstage Renal Disease
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis.
- Trial name
- ACHIEVE (NCT03020303)
- Testing
- Spironolactone 25Mg Tablet
- Where
- 141 sites in Australia, Brazil and 10 more
- Volunteers
- 2,538 people
- Sponsor
- Hamilton Health Sciences Corporation
Endstage Renal Disease, Direct Oral Anticoagulants (DOACs)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1].
- Conditions
- Endstage Renal Disease, Direct Oral Anticoagulants (DOACs), Arteriovenous Fistula, Arteriovenous Fistula Occlusion
- Trial name
- NCT07559942
- Testing
- Apixaban
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Combined military hospital lahore
Endstage Kidney Disease
Implementing "Explore Transplant"- A Pilot Study
Patients with End Stage Kidney Disease (ESKD) require Renal Replacement Therapy (RRT) in order to survive, be it dialysis or kidney transplantation (KT).
- Trial name
- NCT03046732
- Testing
- Implementing "Explore Transplant" Education
- Where
- 2 sites in Canada
- Volunteers
- 227 people
- Sponsor
- University Health Network, Toronto
Cardiovascular Diseases, Cardiovascular Abnormalities
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease
- Trial name
- NCT02966028
- Testing
- SNF472
- Where
- 75 sites in United States, Spain and 1 more
- Volunteers
- 274 people
- Sponsor
- Sanifit Therapeutics S. A.
Coronary Calcification, Endstage Renal Disease
Vitamin D and Carboxy PTH Fragments in Coronary Calcification
Arterial calcification within the coronaries and other vessels is greatly accelerated among patients with chronic or end-stage kidney disease.
- Conditions
- Coronary Calcification, Endstage Renal Disease, Parathyroid Hormone
- Trial name
- NCT00502268
- Testing
- Doxercalciferol administration, Doxercalciferol administered by 1-84-7-84
- Where
- United States
- Sponsor
- Southeast Renal Research Institute
Endstage Renal Disease
Parathyroidectomy in Endstage Renal Disease
To test the hypothesis that total parathyroidectomy retards cardiovascular calcification, improves bone mineral density, reduces cardiac hypertrophy and arterial stiffening in end-stage renal disease patients on maintenance…
- Trial name
- NCT00745719
- Testing
- parathyroidectomy
- Where
- Hong Kong
- Volunteers
- 122 people
- Sponsor
- The University of Hong Kong
Vitamin K Supplementation, Endstage Renal Disease
Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients
Cardiovascular disease (CVD) is the most frequent cause of death in patients (ptt.) with chronic kidney disease (CKD). Compared to the general population death due to CVD is 10-20 times higher in CKD ptt.
- Conditions
- Vitamin K Supplementation, Endstage Renal Disease, Cardiovascular Disease, Bone Disease
- Trial name
- RenaKvit (NCT02976246)
- Testing
- Vitamin K2 (MK7)
- Where
- Denmark
- Volunteers
- 123 people
- Sponsor
- Zealand University Hospital
Endstage Renal Disease
Sevelamer Hydrochloride in Peritoneal Dialysis Patients
To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression of cardiovascular calcification.
- Trial name
- SERENE (NCT00745589)
- Testing
- sevelamer hydrochloride
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
Endstage Renal Disease
Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
Patients undergoing chronic dialysis are at a substantially increased risk of cardiac death. The reasons for this excess cardiovascular mortality are only partly understood.
- Trial name
- RACE (NCT02207153)
- Where
- Switzerland
- Volunteers
- 217 people
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Kidney Disease, Endstage Renal Disease
Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis
This is a pilot, single-center, randomized trial of 90 subjects to evaluate complication rates and functional status decline in subjects age 65 years and older referred for vascular access placement.
- Trial name
- NCT02981706
- Testing
- Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Endstage Renal Disease
The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum
This is a single-center, prospective, open-label, controlled, randomized, cross-over study in 34 prevalent end-stage renal disease patients on chronic hemodialysis treatment with hyperphosphatemia.
- Trial name
- NCT03010072
- Testing
- low-dose sucroferric oxyhydroxide, high-dose sucroferric oxyhydroxide
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Prim. Priv. Doz. Dr. Daniel Cejka
Endstage Renal Disease
Data Collection for Next Generation Ultrasound Technology Development
The study is designed to collect data from a ultrasound device being used to evaluate feasibility of next generation algorithms for ultrasound data processing and does not test any health outcome.
- Trial name
- NCT02946229
- Testing
- Ultrasound scan
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- GE Healthcare
Endstage Renal Disease
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
The purpose of this trial is to examine the effect of increasing dialyse magnesium on serum calcification propensity in subjects with end-stage renal disease treated with haemodialysis.
- Trial name
- NCT02977117
- Testing
- Dialysate magnesium (1.0 mmol/L), Dialysate magnesium (0.5 mmol/L)
- Where
- Denmark
- Volunteers
- 59 people
- Sponsor
- Iain Bressendorff
Endstage Renal Disease
Improving Adherence in Renal Dialysis Patients Through Electronic Interventions
Dialysis treatment non-adherence is a prevalent problem among the end-stage renal population receiving chronic hemodialysis. The complications associated with missed or shortened dialysis sessions are serious and frequently…
- Trial name
- NCT02970201
- Testing
- EpxDialysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Endothelial Dysfunction, Endstage Renal Disease
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
The Purpose of this study is to determine if the Febuxostat has an effect on endothelial dysfunction on hemodialysis patients.
- Trial name
- NCT02866214
- Testing
- Febuxostat
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Diabetes Mellitus, Endstage Renal Disease
A Podiatry Led MDT Intervention to Reduce the Burden of Foot Disease in Patients With End Stage Kidney Failure
Observational studies clearly show that people with diabetes and end-stage kidney failure have an increased risk of foot ulceration and leg amputation. However, there is very little evidence on addressing this problem.
- Trial name
- NCT03054454
- Testing
- Podiatry
- Volunteers
- 32 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Endstage Renal Disease, Secondary Hyperparathyroidism
Intravenous Paricalcitol in Chronic Hemodialysis Patients
This study aims to provide intravenous paritcalcitol treatment for the sick and poor hemodialysis patients with severe secondary hyperparathyroidism (SHPT) resistant to existing vitamin D analogs therapy or with hypercalcemia…
- Trial name
- NCT03023748
- Testing
- Intravenous Paricalcitol
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Endstage Renal Disease, Diabetes
Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients
To test the hypothesis that PPAR-gamma agonist, rosiglitazone, induces carotid plaque regression in diabetic ESRD patients on maintenance PD via its anti-inflammatory property.
- Trial name
- NCT00745914
- Testing
- Pioglitazone
- Where
- 2 sites in Hong Kong
- Volunteers
- 22 people
- Sponsor
- The University of Hong Kong
Endstage Renal Disease
Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis
End-stage renal disease (ESRD) is associated with multiple comorbidities such as cardiovascular disease, anemia, mineral and bone disorders, malnutrition, body wasting, muscle loss (sarcopenia), neurological problems and…
- Trial name
- PLAN (NCT02976688)
- Testing
- Sodium Propionate
- Volunteers
- 15 people
- Sponsor
- Azienda Sanitaria ASL Avellino 2
Endstage Renal Disease
LMWH Infusion as Anticoagulation for Home HD
There is a lack of data in the literature about the use of low-molecular weight heparin (LMWH) as anticoagulation for nocturnal home hemodialysis (NHHD).
- Trial name
- NCT02957877
- Testing
- Nadroparin, Unfractionated heparin
- Where
- Hong Kong
- Volunteers
- 12 people
- Sponsor
- Alice Ho Miu Ling Nethersole Hospital